{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T23:53:23Z","timestamp":1776988403015,"version":"3.51.4"},"reference-count":79,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.clim.2013.02.014","type":"journal-article","created":{"date-parts":[[2013,3,5]],"date-time":"2013-03-05T14:05:38Z","timestamp":1362492338000},"page":"313-321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["Targeting the complement system in systemic lupus erythematosus and other diseases"],"prefix":"10.1016","volume":"148","author":[{"given":"Maria-Louise","family":"Barilla-LaBarca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiley","family":"Toder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Furie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clim.2013.02.014_bb0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/ng0598-3","article-title":"The lupus paradox","volume":"19","author":"Carroll","year":"1998","journal-title":"Nat. Genet."},{"issue":"1 Pt 2","key":"10.1016\/j.clim.2013.02.014_bb0010","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1006\/clim.1999.4813","article-title":"A protective role for innate immunity in autoimmune disease","volume":"95","author":"Carroll","year":"2000","journal-title":"Clin. Immunol."},{"issue":"8","key":"10.1016\/j.clim.2013.02.014_bb0015","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/90686","article-title":"Contribution of the innate immune system to autoimmune myocarditis: a role for complement","volume":"2","author":"Kaya","year":"2001","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.clim.2013.02.014_bb0020","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.4049\/jimmunol.169.4.2126","article-title":"Mice deficient in complement receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody repertoire","volume":"169","author":"Fleming","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2013.02.014_bb0025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0065-2776(08)60908-6","article-title":"The role of complement in B cell activation and tolerance","volume":"74","author":"Carroll","year":"2000","journal-title":"Adv. Immunol."},{"issue":"1","key":"10.1016\/j.clim.2013.02.014_bb0030","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00002281-200301000-00010","article-title":"Rheumatic syndromes associated with complement deficiency","volume":"15","author":"Barilla-LaBarca","year":"2003","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.clim.2013.02.014_bb0035","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1600-065X.2008.00641.x","article-title":"The spectrum of complement alternative pathway-mediated diseases","volume":"223","author":"Holers","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.clim.2013.02.014_bb0040","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0065-2776(01)76021-X","article-title":"Systemic lupus erythematosus, complement deficiency, and apoptosis","volume":"76","author":"Pickering","year":"2000","journal-title":"Adv. Immunol."},{"issue":"3","key":"10.1016\/j.clim.2013.02.014_bb0045","first-page":"305","article-title":"Mannose-binding lectin: structure, function, genetics and disease associations","volume":"2","author":"Turner","year":"2000","journal-title":"Rev. Immunogenet."},{"issue":"12","key":"10.1016\/j.clim.2013.02.014_bb0050","doi-asserted-by":"crossref","first-page":"3966","DOI":"10.1002\/art.21484","article-title":"The mannose-binding lectin gene polymorphisms and systemic lupus erythematosus: two case-control studies and a meta-analysis","volume":"52","author":"Lee","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.clim.2013.02.014_bb0055","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.4049\/jimmunol.168.3.1036","article-title":"Complement C4 is protective for lupus disease independent of C3","volume":"168","author":"Einav","year":"2002","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.clim.2013.02.014_bb0060","doi-asserted-by":"crossref","first-page":"6444","DOI":"10.4049\/jimmunol.166.10.6444","article-title":"Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL\/lpr mice","volume":"166","author":"Sekine","year":"2001","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.clim.2013.02.014_bb0065","doi-asserted-by":"crossref","first-page":"786","DOI":"10.4049\/jimmunol.164.2.786","article-title":"Modulation of renal disease in MRL\/lpr mice genetically deficient in the alternative complement pathway factor B","volume":"164","author":"Watanabe","year":"2000","journal-title":"J. Immunol."},{"issue":"16","key":"10.1016\/j.clim.2013.02.014_bb0070","doi-asserted-by":"crossref","first-page":"8563","DOI":"10.1073\/pnas.93.16.8563","article-title":"Amelioration of lupus-like autoimmune disease in NZB\/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5","volume":"93","author":"Wang","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.clim.2013.02.014_bb0075","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1523-1755.2004.00371.x","article-title":"Effects of complement factor D deficiency on the renal disease of MRL\/lpr mice","volume":"65","author":"Elliott","year":"2004","journal-title":"Kidney Int."},{"issue":"4\u20135","key":"10.1016\/j.clim.2013.02.014_bb0080","first-page":"277-277","article-title":"Regulation of the classical complement pathway: role of membrane cofactor protein (MCP; CD46)","volume":"36","author":"Barilla-LaBarca","year":"1999","journal-title":"Mol. Immunol."},{"issue":"4","key":"10.1016\/j.clim.2013.02.014_bb0085","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.4049\/jimmunol.181.4.2732","article-title":"Membrane protein Crry maintains homeostasis of the complement system","volume":"181","author":"Wu","year":"2008","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.clim.2013.02.014_bb0090","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.4049\/jimmunol.168.12.6298","article-title":"Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells","volume":"168","author":"Barilla-LaBarca","year":"2002","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.clim.2013.02.014_bb0095","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1097\/01.ASN.0000051597.27127.A1","article-title":"Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL\/lpr mice","volume":"14","author":"Bao","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"issue":"9","key":"10.1016\/j.clim.2013.02.014_bb0100","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1172\/JCI25208","article-title":"Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection","volume":"115","author":"Atkinson","year":"2005","journal-title":"J. Clin. Investig."},{"issue":"1\u20132","key":"10.1016\/j.clim.2013.02.014_bb0105","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.molimm.2011.09.015","article-title":"The dual role of complement in the progression of renal disease in NZB\/W F(1) mice and alternative pathway inhibition","volume":"49","author":"Sekine","year":"2011","journal-title":"Mol. Immunol."},{"issue":"4","key":"10.1016\/j.clim.2013.02.014_bb0110","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/art.30222","article-title":"The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL\/lpr mice","volume":"63","author":"Sekine","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"1\u20133","key":"10.1016\/j.clim.2013.02.014_bb0115","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.molimm.2006.07.003","article-title":"Complement receptor 2, natural antibodies and innate immunity: inter-relationships in B cell selection and activation","volume":"44","author":"Holers","year":"2007","journal-title":"Mol. Immunol."},{"issue":"5452","key":"10.1016\/j.clim.2013.02.014_bb0120","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1126\/science.287.5452.498","article-title":"A critical role for murine complement regulator crry in fetomaternal tolerance","volume":"287","author":"Xu","year":"2000","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.clim.2013.02.014_bb0125","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.4049\/jimmunol.176.3.1305","article-title":"The central role of the alternative complement pathway in human disease","volume":"176","author":"Thurman","year":"2006","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.clim.2013.02.014_bb0130","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1074-7613(03)00321-2","article-title":"Negligible role of antibodies and C5 in pregnancy loss associated exclusively with C3-dependent mechanisms through complement alternative pathway","volume":"19","author":"Mao","year":"2003","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.clim.2013.02.014_bb0135","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1084\/jem.200116116","article-title":"Complement C3 activation is required for antiphospholipid antibody-induced fetal loss","volume":"195","author":"Holers","year":"2002","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.clim.2013.02.014_bb0140","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/00005792-198105000-00004","article-title":"Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE)","volume":"60","author":"Lloyd","year":"1981","journal-title":"Medicine (Baltimore)"},{"issue":"2\u20133","key":"10.1016\/j.clim.2013.02.014_bb0145","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF02099021","article-title":"Complement activation and complement receptors in systemic lupus erythematosus","volume":"9","author":"Atkinson","year":"1986","journal-title":"Springer Semin. Immunopathol."},{"issue":"3","key":"10.1016\/j.clim.2013.02.014_bb0150","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/acr.20397","article-title":"Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide","volume":"63","author":"Dall'Era","year":"2011","journal-title":"Arthritis Care Res. (Hoboken)"},{"issue":"10","key":"10.1016\/j.clim.2013.02.014_bb0155","first-page":"1367","article-title":"Clinical and laboratory correlates in responders (by the Systemic Lupus Erythematosus Responder Index) in phase 3 belimumab clinical trials. [Abstract]","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.clim.2013.02.014_bb0160","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.rdc.2009.12.003","article-title":"Cell-bound complement biomarkers for systemic lupus erythematosus: from benchtop to bedside","volume":"36","author":"Liu","year":"2010","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.clim.2013.02.014_bb0165","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1002\/art.34669","article-title":"Measurements of cell bound complement activation products enhance diagnostic performance in systemic lupus erythematosus","volume":"64","author":"Kalunian","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"21","key":"10.1016\/j.clim.2013.02.014_bb0170","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa043731","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis","volume":"353","author":"Ginzler","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.clim.2013.02.014_bb0175","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis","volume":"365","author":"Dooley","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.clim.2013.02.014_bb0180","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis","volume":"20","author":"Appel","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.clim.2013.02.014_bb0185","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.clim.2013.02.014_bb0190","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.clim.2013.02.014_bb0195","doi-asserted-by":"crossref","first-page":"R74","DOI":"10.1186\/ar1942","article-title":"Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus","volume":"8","author":"Dorner","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.clim.2013.02.014_bb0200","article-title":"Efficacy and safety of epratuzumab in patients with moderate\/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study","author":"Wallace","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.clim.2013.02.014_bb0205","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1002\/art.27601","article-title":"The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.clim.2013.02.014_bb0210","first-page":"2469","article-title":"Efficacy and safety of abatacept over 12 months in patients with lupus nephritis: results from a multicenter, randomized, double-blind, placebo-controlled phase II\/III study","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum. - Arthritis Care Res."},{"issue":"9767","key":"10.1016\/j.clim.2013.02.014_bb0215","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.clim.2013.02.014_bb0220","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"19","key":"10.1016\/j.clim.2013.02.014_bb0225","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1001\/jama.291.19.2319","article-title":"Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial","volume":"291","author":"Verrier","year":"2004","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.clim.2013.02.014_bb0230","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.athoracsur.2003.08.054","article-title":"Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass","volume":"77","author":"Shernan","year":"2004","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.clim.2013.02.014_bb0235","series-title":"Innovative Therapies in Autoimmune Diseases","article-title":"A single dose, placebo controlled, double blind, phase I study of the humanized anti-C5 antibody h5G1.1 in patients with systemic lupus erythematosus","author":"Furie","year":"2001"},{"issue":"9","key":"10.1016\/j.clim.2013.02.014_bb0240","first-page":"S489","article-title":"A pilot study of eculizumab in patients with dermatomyositis","volume":"46","author":"Takada","year":"2002","journal-title":"Arthritis Rheum. - Arthritis Care Res."},{"issue":"S9","key":"10.1016\/j.clim.2013.02.014_bb0245","article-title":"A single dose, placebo controlled, double blind, phase I study of the humanized anti-C5 antibody h5G1.1 in patients with rheumatoid arthritis","volume":"42","author":"Jain","year":"1999","journal-title":"Arthritis Rheum. - Arthritis Care Res."},{"issue":"9","key":"10.1016\/j.clim.2013.02.014_bb0250","first-page":"S274","article-title":"Safety and efficacy of the humanized anti-C5 antibody h5G1.1 in patients with rheumatoid arthritis","volume":"44","author":"Tesser","year":"2001","journal-title":"Arthritis Rheum. - Arthritis Care Res."},{"issue":"9","key":"10.1016\/j.clim.2013.02.014_bb0255","first-page":"S214","article-title":"Pharmacokinetics (PK) and pharmacodynamics (PD) of the humanized anti-C5 antibody h5G1.1 in patients with rheumatoid arthritis","volume":"44","author":"Kivitz","year":"2001","journal-title":"Arthritis Rheum. - Arthritis Care Res."},{"issue":"9","key":"10.1016\/j.clim.2013.02.014_bb0260","first-page":"S214","article-title":"Baseline C5b-9 level correlates with CRP and ACR 20 response to the humanized anti-C5 antibody h5G1.1 in patients with rheumatoid arthritis","volume":"44","author":"Burch","year":"2001","journal-title":"Arthritis Rheum. - Arthritis Care Res."},{"issue":"6","key":"10.1016\/j.clim.2013.02.014_bb0265","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMoa031688","article-title":"Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria","volume":"350","author":"Hillmen","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.clim.2013.02.014_bb0270","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","article-title":"Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"111","author":"Brodsky","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clim.2013.02.014_bb0275","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMc0808527","article-title":"Eculizumab for atypical hemolytic-uremic syndrome","volume":"360","author":"Nurnberger","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.clim.2013.02.014_bb0280","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/art.21157","article-title":"Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia","volume":"52","author":"Pierangeli","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.clim.2013.02.014_bb0285","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/art.34440","article-title":"Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab","volume":"64","author":"Shapira","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"7","key":"10.1016\/j.clim.2013.02.014_bb0290","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1177\/0961203310389099","article-title":"Eculizumab and renal transplantation in a patient with catastrophic antiphospholipid syndrome: effect of heparin on complement activation","volume":"20","author":"Velik-Salchner","year":"2011","journal-title":"Lupus"},{"issue":"18","key":"10.1016\/j.clim.2013.02.014_bb0295","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1056\/NEJMc0910965","article-title":"Eculizumab and renal transplantation in a patient with CAPS","volume":"362","author":"Lonze","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2013.02.014_bb0300","first-page":"668","article-title":"Eculizumab (C5 complement inhibitor) in the treatment of idiopathic membranous nephropathy [abstract]","volume":"13","author":"Appel","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.clim.2013.02.014_bb0305","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2215\/CJN.12901211","article-title":"Eculizumab for dense deposit disease and C3 glomerulonephritis","volume":"7","author":"Bomback","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"12","key":"10.1016\/j.clim.2013.02.014_bb0310","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1056\/NEJMc1106619","article-title":"Eculizumab and refractory membranoproliferative glomerulonephritis","volume":"366","author":"Radhakrishnan","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.clim.2013.02.014_bb0315","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJMc1111953","article-title":"Eculizumab for the treatment of dense-deposit disease","volume":"366","author":"Vivarelli","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.clim.2013.02.014_bb0320","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1681\/ASN.2011121186","article-title":"Pathology after eculizumab in dense deposit disease and C3 GN","volume":"23","author":"Herlitz","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"issue":"5720","key":"10.1016\/j.clim.2013.02.014_bb0325","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1126\/science.1110189","article-title":"Complement factor H polymorphism and age-related macular degeneration","volume":"308","author":"Edwards","year":"2005","journal-title":"Science"},{"issue":"5720","key":"10.1016\/j.clim.2013.02.014_bb0330","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1126\/science.1110359","article-title":"Complement factor H variant increases the risk of age-related macular degeneration","volume":"308","author":"Haines","year":"2005","journal-title":"Science"},{"issue":"5720","key":"10.1016\/j.clim.2013.02.014_bb0335","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1126\/science.1109557","article-title":"Complement factor H polymorphism in age-related macular degeneration","volume":"308","author":"Klein","year":"2005","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.clim.2013.02.014_bb0340","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/ng1750","article-title":"Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration","volume":"38","author":"Gold","year":"2006","journal-title":"Nat. Genet."},{"key":"10.1016\/j.clim.2013.02.014_bb0345","article-title":"Dry AMD: the role of complement","author":"Punjabi","year":"2012","journal-title":"Rev. Ophthalmol."},{"issue":"6","key":"10.1016\/j.clim.2013.02.014_bb0350","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0022-5223(19)39061-0","article-title":"Complement and the damaging effects of cardiopulmonary bypass","volume":"86","author":"Kirklin","year":"1983","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"3","key":"10.1016\/j.clim.2013.02.014_bb0355","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.athoracsur.2006.02.024","article-title":"Effect of pexelizumab in coronary artery bypass graft surgery with extended aortic cross-clamp time","volume":"82","author":"Smith","year":"2006","journal-title":"Ann. Thorac. Surg."},{"issue":"2","key":"10.1016\/j.clim.2013.02.014_bb0360","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.athoracsur.2005.12.035","article-title":"Pexelizumab reduces death and myocardial infarction in higher risk cardiac surgical patients","volume":"82","author":"Haverich","year":"2006","journal-title":"Ann. Thorac. Surg."},{"issue":"11 Suppl. 1","key":"10.1016\/j.clim.2013.02.014_bb0365","first-page":"II274","article-title":"Soluble human complement receptor 1 limits ischemic damage in cardiac surgery patients at high risk requiring cardiopulmonary bypass","volume":"110","author":"Lazar","year":"2004","journal-title":"Circulation"},{"issue":"11 Suppl.","key":"10.1016\/j.clim.2013.02.014_bb0370","first-page":"I83","article-title":"Beneficial effects of complement inhibition with soluble complement receptor 1 (TP10) during cardiac surgery: is there a gender difference?","volume":"116","author":"Lazar","year":"2007","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.clim.2013.02.014_bb0375","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ahj.2003.07.004","article-title":"Pharmacokinetics and safety of TP10, soluble complement receptor 1, in infants undergoing cardiopulmonary bypass","volume":"147","author":"Li","year":"2004","journal-title":"Am. Hear. J."},{"issue":"2","key":"10.1016\/j.clim.2013.02.014_bb0380","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jtcvs.2004.06.048","article-title":"A randomized, placebo-controlled trial of complement inhibition in ischemia\u2013reperfusion injury after lung transplantation in human beings","volume":"129","author":"Keshavjee","year":"2005","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"14","key":"10.1016\/j.clim.2013.02.014_bb0385","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.molimm.2011.04.014","article-title":"Inhibiting the C5\u2013C5a receptor axis","volume":"48","author":"Woodruff","year":"2011","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.clim.2013.02.014_bb0390","series-title":"49th European Renal Association\u2013European Dialysis and Transplant Association (ERA\u2013EDTA) Congress","article-title":"Clinical dose selection of the C5a receptor antagonist CCX168 for the phase 2 ANCA-associated renal vasculitis clinical trial (the CLEAR trial)","author":"Dairaghi","year":"2012"},{"key":"10.1016\/j.clim.2013.02.014_bb0395","series-title":"49th European Renal Association\u2013European Dialysis and Transplant Association (ERA\u2013EDTA) Congress","article-title":"Oral C5a receptor antagonist CCX168 in a phase 2 clinical trial in ANCA-associated renal vasculitis","author":"Bekker","year":"2012"}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661613000521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661613000521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T21:59:22Z","timestamp":1715032762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661613000521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":79,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S1521661613000521"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2013.02.014","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the complement system in systemic lupus erythematosus and other diseases","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2013.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}